AngioDynamics, Inc. vs. Boston Scientific Corp.
Boston Scientific Corp. (BSX) comes out ahead, leading on 7 of 8 compared factors.
Size & Scale
| ANGO | BSX | |
|---|---|---|
| Market Cap | $635.28 million | $63.11 billion |
| Revenue (TTM) | $320.17 million | $21.00 billion |
| Net Income (TTM) | $-36,742,000 | $3.67 billion |
BSX leads on 3 of 3 size & scale factors.
Valuation
| ANGO | BSX | |
|---|---|---|
| P/E Ratio | — | 17.55 |
| Price / Book | 3.72 | 2.51 |
| Price / Sales | 1.98 | 3.01 |
ANGO and BSX split the valuation factors evenly.
Profitability
| ANGO | BSX | |
|---|---|---|
| Net Margin | -11.48% | 17.47% |
| Return on Equity | -21.51% | 14.58% |
BSX leads on 2 of 2 profitability factors.
Risk & Sentiment
| ANGO | BSX | |
|---|---|---|
| Short Interest | 4.46% | 0.72% |
BSX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ANGO overview, ANGO financials, BSX overview, BSX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.